<DOC>
	<DOCNO>NCT00003239</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining biological therapy chemotherapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness chemotherapy cytarabine homoharringtonine biological therapy interferon alfa treat patient chronic phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Chemotherapy Biological Therapy Treating Patients With Chronic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effectiveness low dose cytarabine , homoharringtonine , interferon alfa stimulate complete cytogenic response patient Philadelphia chromosome positive early chronic phase chronic myelogenous leukemia . II . Evaluate duration cytogenic response patient treatment . III . Determine differential success rate analyze result prognostic subset ( e.g. , risk group , splenomegaly , thrombocytosis , age , etc . ) patient population . OUTLINE : Patients receive debulking therapy consist hydroxyurea blood count proper level . Patients receive interferon alfa cytarabine daily subcutaneous injection . Homoharringtonine administer continuous infusion day 1-5 . Treatment continue 5-7 year absence unacceptable toxicity disease progression ( accelerate blastic phase CML ) . If complete remission achieve , peripheral blood stem cell collect . Patients follow every 3 month first year every 6 month thereafter . PROJECTED ACCRUAL : A total 100 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Homoharringtonine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Harringtonines</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically confirm early chronic phase chronic myelogenous leukemia ( CML ) Diagnosed within 12 month Philadelphia chromosome positive OR bcr positive No late chronic phase , accelerated phase , blastic phase CML PATIENT CHARACTERISTICS : Age : 12 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 2 mg/dL Renal : Creatinine le 2 mg/dL Cardiovascular : No severe heart disease Other : No psychosis Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Less 1 month prior interferon alfa Chemotherapy : Less 1 month prior cytarabine Prior hydroxyurea allow Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>Homoharringtonine</keyword>
	<keyword>HHT</keyword>
	<keyword>cephalotaxus alkaloid</keyword>
	<keyword>cytarabine</keyword>
	<keyword>Interferon Alpha 2-A</keyword>
	<keyword>Roferon-A</keyword>
	<keyword>Ara-C</keyword>
	<keyword>DepotCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
</DOC>